Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

AbCellera Biologics Inc. reports results for the quarter ended September 30 - Earnings Summary

AbCellera Biologics Inc. reports results for the quarter ended September 30 - Earnings Summary
  • AbCellera Biologics Inc. ABCL.OQ reported a quarterly adjusted loss of 13 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -19 cents. The mean expectation of twelve analysts for the quarter was for a loss of 17 cents per share. Wall Street expected results to range from -20 cents to -11 cents per share.

  • Revenue rose 18.8% to $10.64 million from a year ago; analysts expected $8.42 million.

  • AbCellera Biologics Inc.'s reported EPS for the quarter was a loss of 13 cents​.

  • The company reported a quarterly loss of $40.76 million.

  • AbCellera Biologics Inc. shares had fallen by 18.6% this quarter and gained 247.4% so far this year.

FORECAST CHANGES

  • The mean earnings estimate of analysts had risen by about 4% in the last three months.​

  • In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

  • Wall Street's median 12-month price target for AbCellera Biologics Inc. is $15.00, about 20.8% above its last closing price of $11.88

This summary was machine generated from LSEG data November 9 at 10:39 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Sep. 30 2026

-0.17

-0.13

Beat

Jun. 30 2026

-0.14

-0.18

Missed

Mar. 31 2026

-0.20

-0.14

Beat

Dec. 31 2025

-0.17

-0.03

Beat

Recent news on AbCellera Biologics

See all news